Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update Read more about Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor Read more about Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
Fennec Announces Results of Annual Meeting Read more about Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences Read more about Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update Read more about Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™ Read more about Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™
Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference Read more about Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark™ Read more about Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark™
Fennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update Read more about Fennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update
Fennec Pharmaceuticals Announces Management Change Read more about Fennec Pharmaceuticals Announces Management Change
